Development and characterization of metal oxide nanoparticles for the delivery of anticancer drug

Figures & data

Table I. Size and size distribution of blank ZnO nanoparticles.

S. no.	Zinc Nitrate (M)	Sodium Hydroxide (M)	Starch (%w/v)	Size (nm)	PDI
1.	0.1	0.05	0.5	Unstable	−
2.	0.1	0.1	0.5	412.1 ± 3.23	0.325 ± 0.04
3.	0.1	0.15	0.5	728.4 ± 5.31	0.427 ± 0.02
4.	0.1	0.2	0.5	890.3 ± 6.26	0.409 ± 0.06
5.	0.05	0.1	0.5	Unstable	−
6.	0.15	0.1	0.5	612.4 ± 5.19	0.392 ± 0.03
7.	0.2	0.1	0.5	852.7 ± 7.22	0.512 ± 0.03
8.	0.3	0.1	0.5	958.4 ± 8.33	0.531 ± 0.04
9.	0.1	0.1	0.4	Unstable	−
10.	0.1	0.1	0.3	Unstable	−
11.	0.1	0.1	0.2	Unstable	−

Figure 1. Schematic diagram showing the preparation of DOX-loaded ZnO nanoparticles.

Table II. Size, size distribution, and entrapment efficiency of DOX-loaded ZnO nanoparticles.

S. No.	Amount Added (mg/ml)	Amount Entrapped (mg)	% Entrapment	Size (nm)	PDI
1.	0.05	4.083 ± 0.12	81.66 ± 0.88	472.3 ± 3.15	0.326 ± 0.03
2.	0.08	6.732 ± 0.10	84.15 ± 0.80	475.1 ± 2.62	0.376 ± 0.01
3.	0.10	8.576 ± 0.16	85.76 ± 1.24	476.4 ± 2.51	0.312 ± 0.02
4.	0.12	8.615 ± 0.11	72.62 ± 0.84	477.2 ± 3.23	0.427 ± 0.06

Figure 2. SEM Image of DOX-loaded ZnO Nanoparticles.

Table III. Size of the nanoparticles after storage.

S. No.	Time Interval (h)	Size (nm)
1.	Initial	476.4 ± 2.51
2.	4	478.3 ± 4.5
3.	8	483.8 ± 3.9
4.	12	485.2 ± 7.6
5.	24	487.6 ± 6.8

Figure 3. In vitro drug release profile of the DOX-loaded ZnO nanoparticles.

Figure 4. Uptake of DOX formulations by MCF-7 cells. *p < 0.5 and **p < 0.01, when compared with free DOX.

Figure 5. Percent cell viability of MCF-7 cells incubated with different formulations for 24 h. *p < 0.5 and **p < 0.01 when compared with free DOX.